Category: Pharmacology, Toxicology and Pharmaceutics
Zuranolone was approved for postpartum depression, not major depressive disorder
Analysis of zuranolone approval reveals how fast-track designations and reduced evidentiary thresholds in drug regulation may inadequately balance innovation with public health protection.
Rivaroxaban controversy linked to synthetic certainty
Analysis of regulatory closure and synthetic certainization in rivaroxaban authorization, examining how institutional power consolidated therapeutic claims despite device defects.
Meloxicam approval in cats is questioned over kidney risk and missing trial data
Examine injectable meloxicam approval for cats, regulatory data discrepancies, acute kidney injury risks, and pharmaceutical sponsorship conflicts in veterinary medicine.
FAERS data show post-marketing adverse event patterns with casimersen
Pharmacovigilance analysis of casimersen adverse event reporting patterns using FAERS database with characterization of preferred terms, organ systems, and time-to-onset distributions.
